The Perjeta biosimilar race has a new dated entrant. On 14 October 2026 Biocon said it had reached a global settlement and licence agreement with Genentech, part of the Roche Group, over Pebrilzo, its pertuzumab biosimilar. The company states that the deal permits launch in the European Union and United Kingdom in the first quarter of 2027 and in the United States in the third quarter of 2028, subject to regulatory approvals, with other markets between 2026 and 2028.
This report looks at where Pebrilzo sits among pertuzumab competitors, what regulators have and have not said, and which questions the announcement leaves unanswered.
Perjeta biosimilar: key takeaways
- Pebrilzo is Biocon’s pertuzumab biosimilar, referencing Roche’s Perjeta for HER2-positive breast cancer.
- Company-stated launch dates: EU and UK in Q1 2027, US in Q3 2028.
- The EMA lists a positive opinion dated 17 September 2026. A European Commission decision was not shown when we checked.
- The FDA has already approved a different Perjeta biosimilar, so Pebrilzo will not be first in the US.
- Money terms and patent specifics were not disclosed.
Where Pebrilzo stands among Perjeta biosimilar candidates
Pertuzumab is a monoclonal antibody that binds the HER2 receptor and is used alongside trastuzumab and chemotherapy. The EMA’s Perjeta record shows the reference medicine has been authorised in the EU since 4 March 2013 under Roche Registration GmbH. For years the antibody had no direct competitor. That is changing: the US Food and Drug Administration approved Poherdy (pertuzumab-dpzb) on 11 November 2025 as the first Perjeta biosimilar, and describes it as interchangeable with the reference product.
Biocon’s product has taken a European route. The European Medicines Agency (EMA) shows its human medicines committee issued a positive opinion on 17 September 2026 for Pebrilzo, which it describes as highly similar to Perjeta. A positive opinion is not a licence. The European Commission normally follows with a decision, and that decision was not displayed when we looked. The page also lists different applicant companies in different sections, so we do not say which entity will hold the authorisation.
Why a settlement matters for a Perjeta biosimilar launch
Biologic medicines are protected by layers of patents covering the molecule, manufacturing and use. A biosimilar developer can win approval and still be barred from selling if those patents are enforced. A settlement and licence replaces that uncertainty with a date. Biocon calls these its earliest licensed launch dates, which is a way of saying that Genentech has agreed not to block sales from then on, while approvals remain a separate hurdle.
We could not read the agreement. The companies have not published the patents, the royalty terms or the list of rest-of-world countries, and Biocon’s release page was not accessible to our reader, so we rely on consistent reports of its content. Treat the schedule as Biocon’s account.
Settlements of this kind are common in biologics because litigation is slow and its outcome uncertain for both sides. The originator keeps a period of protected sales, and the challenger gets a firm entry date without waiting for a court. What each side gives up is exactly the information that has not been made public here.
The timing gap between Europe and the US
By our calculation, using quarter midpoints, the US date comes about a year and a half after the European one. That gap is analysis, not a disclosed figure. One plausible reading, which we flag as interpretation, is that US patent protection runs longer or that US litigation was harder to resolve. The announcement does not say.
For purchasers, the sequence matters. European hospitals and health systems may see a second or third pertuzumab option in 2027, while US buyers may already have a biosimilar by then. A later entrant usually has to compete on price, supply reliability and contracting rather than novelty.
What the new competitor could mean for patients
The EMA indications for Pebrilzo mirror the reference medicine: pertuzumab with trastuzumab and docetaxel for previously untreated HER2-positive metastatic or locally recurrent unresectable breast cancer, and with trastuzumab and chemotherapy before and after surgery for high-risk early disease. A biosimilar does not alter these uses or the treatment pathway. Its effect, if any, is on cost and access, and no price has been announced. Readers following drug-pricing and supply stories may also want our report on the Par Health argatroban recall, or more coverage in pharmaceuticals.
Risks and caveats for the Perjeta biosimilar
- Regulatory approval is still needed in each market, and the European Commission decision was unconfirmed at the time of checking.
- We found no UK or US regulatory status for Pebrilzo.
- The launch schedule is Biocon’s statement; the contract has not been published.
- A competitor is already approved in the US, which may narrow the opportunity by 2028.
In our assessment, the settlement is good news for Biocon’s European plans because it clears the legal path ahead of a likely authorisation, but the commercial result will depend on pricing and on how quickly hospitals switch. We would treat the US 2028 date cautiously, since the market may look very different by then.
What to watch next
- The European Commission decision on Pebrilzo.
- UK and US filing or approval news.
- Which rest-of-world markets are covered.
- Pricing signals from early European tenders.
Frequently asked questions
What is a Perjeta biosimilar?
A biological medicine shown to be highly similar to Perjeta (pertuzumab), the HER2-targeted antibody made by Roche’s Genentech.
Which biosimilar is already approved?
The FDA approved Poherdy (pertuzumab-dpzb) on 11 November 2025 as the first US Perjeta biosimilar.
When will Biocon’s Perjeta biosimilar launch?
Biocon states Q1 2027 in the EU and UK and Q3 2028 in the US, subject to regulatory approvals.
Is Pebrilzo approved in the EU?
The EMA lists a positive opinion dated 17 September 2026. We did not see a European Commission decision.
How we reported this: we relied on Biocon’s announcement of 14 October 2026 as reported, EMA product pages for Pebrilzo and Perjeta, and an FDA bulletin on Poherdy. Figures labelled as ours are our own calculations. Last updated: 15 October 2026. This article is news reporting and not medical or investment advice.
